KR20230163413A - 알카프타딘을 포함하는 비강 조성물 - Google Patents

알카프타딘을 포함하는 비강 조성물 Download PDF

Info

Publication number
KR20230163413A
KR20230163413A KR1020237033154A KR20237033154A KR20230163413A KR 20230163413 A KR20230163413 A KR 20230163413A KR 1020237033154 A KR1020237033154 A KR 1020237033154A KR 20237033154 A KR20237033154 A KR 20237033154A KR 20230163413 A KR20230163413 A KR 20230163413A
Authority
KR
South Korea
Prior art keywords
composition
nasal
alcaftadine
pharmaceutical composition
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237033154A
Other languages
English (en)
Korean (ko)
Inventor
아킬레시 샤르마
바바사헵 어웨어
비라즈 샤
아몰 아이왈레
Original Assignee
알켐 라보라토리즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알켐 라보라토리즈 리미티드 filed Critical 알켐 라보라토리즈 리미티드
Publication of KR20230163413A publication Critical patent/KR20230163413A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020237033154A 2021-04-01 2021-06-14 알카프타딘을 포함하는 비강 조성물 Pending KR20230163413A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202121015680 2021-04-01
IN202121015680 2021-04-01
PCT/IB2021/055221 WO2022208146A1 (en) 2021-04-01 2021-06-14 Nasal compositions comprising alcaftadine

Publications (1)

Publication Number Publication Date
KR20230163413A true KR20230163413A (ko) 2023-11-30

Family

ID=76523258

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237033154A Pending KR20230163413A (ko) 2021-04-01 2021-06-14 알카프타딘을 포함하는 비강 조성물

Country Status (12)

Country Link
US (6) US20240173331A1 (enExample)
EP (1) EP4312973A1 (enExample)
JP (1) JP2024512121A (enExample)
KR (1) KR20230163413A (enExample)
CN (1) CN117120029A (enExample)
AU (1) AU2021437358A1 (enExample)
BR (1) BR112023019795A2 (enExample)
CA (1) CA3213156A1 (enExample)
CL (1) CL2023002871A1 (enExample)
MX (1) MX2023011546A (enExample)
WO (1) WO2022208146A1 (enExample)
ZA (1) ZA202308388B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine
CN114504037B (zh) * 2022-01-14 2024-12-03 云南中茶茶业有限公司 一种茶叶发酵瓶用出瓶机
US11992493B1 (en) * 2022-10-25 2024-05-28 Liangdan Sun Use of compound or pharmaceutical derivative thereof in inhibiting CaMK2G protein activity

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE84968T1 (de) 1987-11-13 1993-02-15 Asta Medica Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv 11-(4-Piperidinyl)-imidazo (2,1-b) (3) benzazepine derivatives their preparation and pharmaceutical compositions containing them
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
PT1919450E (pt) 2005-09-01 2014-09-10 Meda Ab Composição lipossomal contendo anti-histamínico e corticosteróide e sua utilização para a preparação de um medicamento para o tratamento de rinite e distúrbios relacionados
SG170044A1 (en) * 2006-03-31 2011-04-29 Vistakon Pharmaceuticals Llc Ocular allergy treatments
BR112013034055A2 (pt) * 2011-06-29 2017-02-07 Allergan Inc alcaftadina para uso no tratamento de urticária
CN102283849A (zh) 2011-06-29 2011-12-21 北京阜康仁生物制药科技有限公司 一种含有阿卡他定的药物组合物
JP7191022B2 (ja) * 2017-07-28 2022-12-16 参天製薬株式会社 アルカフタジン又はその塩を含有する水性医薬組成物
AU2021291684A1 (en) * 2020-06-15 2022-12-08 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
US20240173331A1 (en) * 2021-04-01 2024-05-30 Alkem Laboratories Limited Nasal compositions comprising alcaftadine

Also Published As

Publication number Publication date
US20240173331A1 (en) 2024-05-30
ZA202308388B (en) 2025-11-26
EP4312973A1 (en) 2024-02-07
US20250064825A1 (en) 2025-02-27
US20250064827A1 (en) 2025-02-27
CA3213156A1 (en) 2022-10-06
AU2021437358A1 (en) 2023-09-14
US12274702B2 (en) 2025-04-15
CN117120029A (zh) 2023-11-24
US20250064826A1 (en) 2025-02-27
CL2023002871A1 (es) 2024-01-26
JP2024512121A (ja) 2024-03-18
MX2023011546A (es) 2023-10-06
WO2022208146A1 (en) 2022-10-06
US20250064828A1 (en) 2025-02-27
US20260007682A1 (en) 2026-01-08
BR112023019795A2 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
US12274702B2 (en) Nasal compositions comprising alcaftadine
JP7791119B2 (ja) アルカフタジンとコルチコステロイドの組み合わせ
EP2522365B1 (en) Compositions comprising azelastine and methods of use thereof
JP5683719B2 (ja) ベポタスチン組成物
US20110294897A1 (en) Treating Xerophthalmia With Compounds Increasing Meibomian Gland Secretion
US12290517B2 (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile
US20040242625A1 (en) Nasal delivery of apomorphine
CN103747786A (zh) 比马前列素和溴莫尼定的固定剂量组合
KR102578102B1 (ko) 엔도텔린 수용체 길항제의 국소 안용 제형
JP2025513090A (ja) 眼疾患の治療のためのミコフェノール酸及び／又はベタメタゾンの医薬組成物
US20020002175A1 (en) Nasal delivery of apomorphine in combination with glycol derivatives
CN120884540A (zh) 一种鼻用制剂及其应用
RU2854644C1 (ru) Композиции для интраназального применения, содержащие алкафтадин
JPH11147825A (ja) 粘膜吸収性の向上方法及び粘膜外用剤
RU2818073C2 (ru) Фармацевтическая композиция n,n'-бис[2-(1н-имидазол-4-ил)этил]малонамида
US20250228836A1 (en) Bilastine composition for once-daily parenteral administration
TW202211919A (zh) 蕈毒鹼性促效劑眼用製劑及其用途
CN1389206A (zh) 一种抗白内障眼药和角膜渗透促进剂氮酮的眼科应用
EA041383B1 (ru) Интраназальная композиция, включающая бетагистин

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902